1Potyk D.Treatments for Alzheimer disease[J].South Med J,2005,98 (6):628-635.
2Parsons C G,Steffler A,Danysz W.Memantine:a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad,too much is even worse[J].Neuropharmacology,2007,53(6):699-723.
3Gilling K E,Jatzke C,Parsons C G.Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine[J].Neuropharmacology,2007,53 (3):415-420.
4Volbracht C,Van Beek J,Zhu C,et al.Neuroprotective properties of memantine in different invitro and in vivo models of excitotoxicity[J].Eur J Neurosci,2006,23(10):2611-2622.
1Parsons CG,Danysz W,Quack G.Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data.Neuropharmacology,1999,38:735-767.
2American psychiatric assosition.Diagnostic and statistical manual of mental disorders.4th ed.Washington:American Psychiatric Press,1994.147-154.
3McKhann G,Drachman D,Folstein M,et al.Clinical diagnosis of Alzheimer's disease:report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.Neurology,1984,34:939-944.
5Cacabelos R,Takeda M,Winblad B.The glutamatergic system and neurodegeneration in dementia:preventive strategies in Alzheimer's disease.Int J Geriatr Psychiatry,1999,14:3-47.
6Tariot PN,Farlow MR,Grossberg GT,et al.Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil:a randomized controlled trial.JAMA,2004,291:317-324.
8Winblad B,Poritis N.Memantine in severe dementia:results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).Int J Geriatr Psychiatry,1999,14:135-146.
3Kurz A, Grimmer T. Efficacy of memantine hydrochloride once-daily in Alzheimer's disease [ J-. Expert Opin Pharmacother, 2014,15 (13): 1955-1960.
4Hanson JE, Pare JF, Deng LB, et al. Altered GluN2B NMDA receptor function and synaptic plasticity during early pathology in the PS2APP mouse model of Alzheimer- disease [ J ]. Neurobiol Dis, 2015,74 ( 6 ) : 254 -262.
5Si MT,Ferreira IL,Valero J,et al. Impaired Src signaling and post-syn- aptic actin polymerization in Alzheimer's disease mice hippocampus-- linking NMDA receptors and the reelin pathway[ J]. Exp Neurol,2014, 261 ( 15 ) :698-709.
6Droogsma E,Van Asseh D, Diekhuis M, et al. Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer- disease [ J ]. Int Psychogeriatr,2015,17 (3) : 1-11.
